Mobocertinib has now been fast-tracked and will be made available to NHS England eligible lung cancer patients within weeks. The new drug targeted for treatment of rare, advanced EGFR Exon 20 insertion-positive advanced non-small-cell lung cancer (Exon20 NSCLC), which can not be surgically removed and primarily affects younger non-smokers, will be made available to patients who have already received chemotherapy treatment.
When taken as a tablet Mobocertinib targets the mutation reducing the rate of cancer cells growth, resultant side effects are said to be manageable. Trial results indicate some patients lived for two years following treatment with the breakthrough drug, notably longer than expected for these patients.
Early access to the drug has been granted following approval by the MHRA and as part of an agreement made between NHS England, NICE and drug manufacturer Takeda. This is the fourth drug made available to NHS patients by NHS England through an early national access agreement as a result of the Project Orbis licence, and akin NHS agreements for Osimertinib, Atezolizumab, and Sotorasib. Long Term the NHS is committed to providing the latest pioneering treatments and faster access to patients.
Sajid Javid, Secretary of State for Health and Social Care, stated: “NHS patients are the first in Europe to benefit from this cutting-edge new treatment for lung cancer – mobocertinib is a breakthrough drug which will be a lifeline for those with this rare form of the illness.” “Our early access agreement through Project Orbis, an international partnership, has allowed us to make this drug available on an accelerated timescale – a fantastic example of post-Brexit global collaboration ensuring UK patients receive the best possible care and treatment for cancer”.
Oncology Country Head for Takeda UK and Ireland, Emma Roffe, said: “Takeda is delighted that access to mobocertinib will be expedited for eligible patients with EGFR Exon20 NSCLC who are in dire need of targeted treatment options. The close partnership between Takeda, the MHRA and NHS England to recognise the value of this innovative treatment, is testament to our shared commitment to provide the best care and deliver improved outcomes for patients”.
For more information on Mobocertinib follow
- https://www.nice.org.uk/guidance/indevelopment/gid-ta10881
- https://www.sps.nhs.uk/medicines/mobocertinib/